1993
DOI: 10.1007/bf02786125
|View full text |Cite
|
Sign up to set email alerts
|

Somatostatin analog treatment of pancreatic fistulas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
7
0

Year Published

1994
1994
2011
2011

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 28 publications
(7 citation statements)
references
References 8 publications
0
7
0
Order By: Relevance
“…Somatostatin's action is direct by suppressing glandular secretion (7,16) as well as indirect by suppressing the secretion of gastrointestinal hormones (6,10,16). The reduction of pancreatic juice formation and enzyme secretion enables fistulas to close and ductal leakage to stop (7,13,15), but fistula closure by octreotide treatment was impaired by the existence of a pseudocyst (15). Also, a pancreatic pseudocyst in a 15‐month‐old child, which developed as a complication of the relapsing pancreatitis, did not disappear with octreotide treatment (6).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Somatostatin's action is direct by suppressing glandular secretion (7,16) as well as indirect by suppressing the secretion of gastrointestinal hormones (6,10,16). The reduction of pancreatic juice formation and enzyme secretion enables fistulas to close and ductal leakage to stop (7,13,15), but fistula closure by octreotide treatment was impaired by the existence of a pseudocyst (15). Also, a pancreatic pseudocyst in a 15‐month‐old child, which developed as a complication of the relapsing pancreatitis, did not disappear with octreotide treatment (6).…”
Section: Discussionmentioning
confidence: 99%
“…It has a very short half‐life ranging from 2 to 3 minutes, which limits its function. Octreotide is a long‐acting analogue with a half‐life, of 2 to 5 hours (9,14,15). Octreotide has found a place in the treatment of gastroenterologic (including pancreatic) problems in adults (7,12,14‐16).…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…For these reasons, it seems that it would be the ideal adjunctive drug for the treatment of high-output ECF and numerous series have reported success with its use. Ironically, multiple randomized controlled studies examining somatostatin and octreotide in combination with TPN have demonstrated a significant reduction in fistula output [55][56][57] and improvement in time to closure [58], but there was no effect on mortality or spontaneous closure rates. Currently, a trial of octreotide (100-250 mcg subcutaneously three times a day) is reasonable in cases of biliary, pancreatic, or proximal fistula or if the volume of fistula output is a concern.…”
Section: Pharmacologic Adjunctsmentioning
confidence: 99%